Search clinical trials for: DAG181

Total 36 results

Ansun Biopharma, Inc.

Recruiting

Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study

COVID-19 | Lower Respiratory Tract Infection | Immunocompromised | Parainfluenza

United States, Australia, China, Denmark, France, Hong Kong, Korea, Republic of, Taiwan
Sunshine Lake Pharma Co., Ltd.

Completed

The Safety, Tolerability and Pharmacokinetic Study of Yimitasvir in Healthy Adults Subjects

Chronic Hepatitis c

China
Dongguan HEC TaiGen Biopharmaceuticals Co., Ltd.
Peking University People's Hospital

Completed

To Evaluate Efficacy and Safety in TG-2349 Combination With DAG181 (± Ribavirin) in HCV Genotype I Infected Patients

Cirrhosis | Chronic Hepatics C Virus (HCV) Genotype 1 | Non-Cirrhotic | Treatment naïve

China
Ansun Biopharma, Inc.

Completed

Phase 2B Study on Safety and Therapeutic Efficacy of DAS181 in Adult Subjects With Naturally Acquired Influenza

Influenza

United States
National Institute of Allergy and Infectious Diseases...

Withdrawn

DAS181 in Patients With Parainfluenza

Parainfluenza Infection
Ansun Biopharma, Inc.
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

DAS181 Single Dose Escalation Study in Healthy Adults

Healthy

United States
Ansun Biopharma, Inc.
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Single Dose Escalating Study of DAS181 in Adults

Influenza

United States
Renmin Hospital of Wuhan University
Ansun Biopharma, Inc.

Completed

DAS181 for Severe COVID-19: Compassionate Use

COVID-19

China
Dongguan HEC TaiGen Biopharmaceuticals Co., Ltd.
R&G Pharma Studies Co.,Ltd.

Completed

To Evaluate PK and Safety Profile of Oral MAD of Separately Using TG-2349, DAG181 or Combination in Healthy Chinese Volunteers

Healthy Chinese Volunteers

China
Ansun Biopharma, Inc.

Withdrawn

DAS181 for STOP COVID-19

COVID-19

Italy
Ansun Biopharma, Inc.

Unknown

DAS181 for Patients With Severe Hospitalized Flu and SAD-RVs (COVID-19) (STOP-Flu)

Influenza Infection | SAD-RV Infection and COVID-19

China
Ansun Biopharma, Inc.

Completed

A Phase II, Randomized, Double-blind, Placebo-controlled Study to Examine the Effects of DAS181 in Immunocompromised Subjects With Lower Respiratory Tract Parainfluenza Infection on Supplemental Oxygen (DAS181-2-05)

Parainfluenza

United States
Sunshine Lake Pharma Co., Ltd.

Completed

Pharmacokinetics of Yimitasvir Phosphate Capsule in Subjects With Normal Renal Function and ESRD

Renal Impairment

China
National Institute of Allergy and Infectious Diseases...

Completed

Influenza Antiviral DAS-181-F04 in Healthy Adults

Influenza

United States
National Institute of Allergy and Infectious Diseases...

Completed

Influenza Antiviral DAS181-F03

Influenza

United States
Ansun Biopharma, Inc.

Completed

An Open Label Study to Examine the Effects of DAS181 Administered by Dry Powder Inhaler (DPI) or Nebulized Formulation in Immunocompromised Subjects With Parainfluenza (PIV) Infection (PIV)

Parainfluenza

United States
Ansun Biopharma, Inc.
National Institutes of Health (NIH)

Completed

A Safety Trial of DAS181 (Fludase®) in Adult Subjects With Well-Controlled Asthma or Bronchiectasis (DAS181)

Bronchiectasis | Asthma

United States
Day One Biopharmaceuticals, Inc.

Available

Expanded Access Program (EAP) for Tovorafenib (DAY101) in RAF-Altered, Relapsed or Refractory Low-Grade Glioma

Low-grade Glioma
Sunshine Lake Pharma Co., Ltd.

Completed

Phase 2 Study of Yimitasvir Phosphate Capsules

Chronic HCV Infection

China
Ansun Biopharma, Inc.
National Institutes of Health (NIH)

Completed

Randomized, Double-blind, Placebo Controlled Phase II Study to Examine the Effects of DAS181 in Healthy Adult Subjects With Laboratory Confirmed Influenza

Influenza

United States
Agios Pharmaceuticals, Inc.

Completed

Study of Orally Administered AG-881 in Patients With Advanced Hematologic Malignancies With an IDH1 and/or IDH2 Mutation

Myelodysplastic Syndrome | Hematologic Malignancies | Acute Myeloid Leukemia (AML)

United States, France
University Health Network, Toronto
Centre for Addiction and Mental Health

Recruiting

Psilocybin-Assisted Psychotherapy for Treatment-Resistant Depression: Comparing One Versus Two Doses of Psilocybin (PSI-1V2)

Depression | Mood Disorders | Major Depressive Disorder | Treatment-Resistant Depression

Canada
Sunshine Lake Pharma Co., Ltd.

Completed

Phase 3 Study of Yimitasvir Phosphate Capsules

Chronic HCV Infection

China
Karen D. Wright, MD
National Cancer Institute (NCI); Pacific Pediatric Neuro-Oncology Consortium; Day One Biopharmaceuticals, Inc... and other collaborators

Active, not recruiting

DAY101 In Gliomas and Other Tumors

Low-grade Glioma

United States
Institut de Recherches Internationales Servier

Active, not recruiting

Study of Orally Administered AG-881 in Patients With Advanced Solid Tumors, Including Gliomas, With an IDH1 and/or IDH2 Mutation

Glioma

United States
Day One Biopharmaceuticals, Inc.
Pacific Pediatric Neuro-Oncology Consortium

Recruiting

A Study to Evaluate DAY101 in Pediatric and Young Adult Patients With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors (FIREFLY-1)

Advanced Solid Tumor | Low-grade Glioma

United States, Israel, Korea, Republic of, Denmark, Singapore, Netherlands, Canada, Australia, Germany, Switzerland, United Kingdom
Dongguan HEC TaiGen Biopharmaceuticals Co., Ltd.

Completed

A Phase III Study to Evaluate Efficacy and Safety of TG-2349 in Combination With DAG181 and RBV for HCV Type I Patients

Cirrhosis | Chronic Hepatics C Virus (HCV) Genotype 1 | Non-Cirrhotic | Treatment naïve

China
Agios Pharmaceuticals, Inc.

Completed

A Study to Evaluate AG-881 in Healthy Japanese and Non-Asian Participants

Healthy Volunteers

United States
Agios Pharmaceuticals, Inc.

Completed

A Study to Compare the Relative Bioavailability of Two AG-881 Formulations and Evaluate the Effect of Food and Omeprazole on the Pharmacokinetics of AG-881

Healthy Volunteers

United States
Children's Oncology Group

Not yet recruiting

A Study With DAY101 as a Treatment Option for Progressive, Relapsed, or Refractory Langerhans Cell Histiocytosis

Recurrent Langerhans Cell Histiocytosis | Refractory Langerhans Cell Histiocytosis
Day One Biopharmaceuticals, Inc.
SIOPe Brain Tumor Group LOGGIC Consortium

Recruiting

DAY101 vs. Standard of Care Chemotherapy in Pediatric Patients With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)

Low-grade Glioma

United States, Korea, Republic of, France, Germany, Spain, United Kingdom, Belgium, Denmark, Canada, Italy, Finland, Australia, Ireland, Switzerland, Netherlands, Czechia, Greece, New Zealand, Slovenia, Sweden, Hungary, Singapore, A... and more
Sabine Mueller, MD, PhD
Bristol-Myers Squibb; Day One Biopharmaceuticals, Inc.

Recruiting

Nivolumab and Tovorafenib for Treatment of Craniopharyngioma in Children and Young Adults (PNOC029)

Craniopharyngioma | Craniopharyngioma, Child | Recurrent Craniopharyngioma

United States
Institut de Recherches Internationales Servier

Active, not recruiting

Study of AG-120 and AG-881 in Subjects With Low Grade Glioma

Glioma

United States
Qassim University

Unknown

Worldwide Trends on COVID-19 Research After the Declaration of COVID-19 Pandemic

COVID-19
National Cancer Institute (NCI)

Recruiting

A Study With Tovorafenib (DAY101) as a Treatment Option for Progressive, Relapsed, or Refractory Langerhans Cell Histiocytosis

Recurrent Langerhans Cell Histiocytosis | Refractory Langerhans Cell Histiocytosis

United States, Canada
The Alfred

Unknown

A Study Comparing Continuous Infusion Antibiotics to Standard Treatment for Lung Infections in Cystic Fibrosis (CISTIC)

Cystic Fibrosis

Australia

Search clinical trials for: DAG181

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bulgaria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations